Scalper1 News
Big-cap biotech and IBD 50 stock United Therapeutics (UTHR) missed analysts’ Q1 estimates Tuesday as its drug sales came up short, sending the stock tumbling in early trading. United reported revenue of $327.5 million, up 13% from the year-earlier quarter but some $37 million short of consensus. Non-GAAP earnings per share rose 36% to $2.55, above analysts’ consensus of $2.14, but analysts estimate somewhat differently depending on how they Scalper1 News
Scalper1 News